Ganciclovir Ophthalmic Gel 0.15%: Safety and Efficacy of a New Treatment for Herpes Simplex Keratitis

REFERENCES

• Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci 2005;46:241–247.
   PubMed Web of Science ®Google Scholar
• Khan BF, Pavan-Langston D. Clinical manifestations and treatment modalities in herpes simplex virus of the ocular anterior segment. Int Ophthalmol Clin 2004;44:103–133.
   PubMedGoogle Scholar
• Labetoulle M, Auquier P, Conrad H et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology 2005;112:888–895.
   PubMed Web of Science ®Google Scholar
• Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001;20:1–13.
   PubMed Web of Science ®Google Scholar
• Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989;107:1155–1159.
   PubMed Web of Science ®Google Scholar
• Kaufman HE. Ganciclovir: a promising topical antiviral gel for herpetic keratitis. Expert Rev Ophthalmol 2009;4:367–375.
   Google Scholar
• Kaufman HE, Maloney ED, Nesburn AB. Comparison of specific antiviral agents in herpes simplex keratitis. Invest Ophthalmol 1962;1:686–692.
   PubMedGoogle Scholar
• Kaufman H, Martola EL, Dohlman C. Use of 5-iodo-2′-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch Ophthalmol 1962;68:235–239.
   PubMedGoogle Scholar
• Kaufman HE, Nesburn AB, Maloney ED. IDU therapy of herpes simplex. Arch Ophthalmol 1962;67:583–591.
   PubMedGoogle Scholar
• Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2007;1:CD002898.
   Google Scholar
• Guess S, Stone DU, Chodosh J. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf 2007;5:240–250.
   PubMed Web of Science ®Google Scholar
• Wellings PC, Awdry PN, Bors FH, Jones BR, Brown DC, Kaufman HE. Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers. Am J Ophthalmol 1972;73:932–942.
   PubMed Web of Science ®Google Scholar
• Maudgal PC, Van Damme B, Missotten L. Corneal epithelial dysplasia after trifluridine use. Graefes Arch Clin Exp Ophthalmol 1983;220:6–12.
   PubMed Web of Science ®Google Scholar
• Udell IJ. Trifluridine-associated conjunctival cicatrization. Am J Ophthalmol 1985;99:363–364.
   PubMedGoogle Scholar
• Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003;9:341–352.
   PubMed Web of Science ®Google Scholar
• Locarnini S, Guo K, Lucas R, Gust I. Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. Lancet 1989;2:1225–1226.
   Google Scholar
• Taylor DL, Jeffries DJ, Taylor-Robinson D, Parkin JM, Tyms AS. The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG). FEMS Microbiol Lett 1988;49: 337–341.
   Web of Science ®Google Scholar
• Sirion Therapeutics, Inc. New Drug Application 22–211:ST-605 (Ganciclovir Ophthalmic Gel, 0.15%). November 14, 2008.
   Google Scholar
• Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol 2007;1:441–453.
   PubMedGoogle Scholar
• Zirgan [package insert]. Rochester, NY: Bausch & Lomb, Inc; 2009.
   Google Scholar
• Hoh HB, Hurley C, Claoue C et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol 1996;80:140–143.
   PubMed Web of Science ®Google Scholar
• Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721–729.
   PubMed Web of Science ®Google Scholar
• Castela N, Vermerie N, Chast F et al. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. J Ocul Pharmacol 1994;10:439–451.
   PubMedGoogle Scholar
• Trousdale MD, Nesburn AB, Willey DE, Taaid H. Efficacy of BW759 (9-[[2-hydroxy-1(hydroxymethyl)ethoxy]methyl]guanine) against herpes simplex virus type 1 keratitis in rabbits. Curr Eye Res 1984;3:1007–1015.
   PubMed Web of Science ®Google Scholar
• Shiota H, Naito T, Mimura Y. Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea. Curr Eye Res 1987;6:241–245.
   PubMed Web of Science ®Google Scholar
• Varnell ED, Kaufman HE. Comparison of ganciclovir ophthalmic gel and trifluridine drops for the treatment of experimental herpetic keratitis. Presented at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology; April 27–May 1, 2008; Fort Lauderdale, FL.
   Google Scholar
• Chibrel H, Elena PP, Khosravi E. Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed epithelium. Invest Ophthalmol Vis Sci 1993;34:1712–1734.
   Google Scholar
• Lowe E, Jiang S, Proksch JW. Rapid ocular penetration of ganciclovir with topical administration of Zirgan® to rabbits. Poster presented at the 2011 Annual Meeting of the Association for Research in Vision and Ophthalmology; April 30–May 5, 2011; Fort Lauderdale, FL.
   Google Scholar
• Food and Drug Administration. Center for Drug Evaluation and Research. Zirgan Clin Pharmacol Biopharm Rev Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211_zirgan_toc.cfm. Accessed 3 June 2011.
   Google Scholar
• Pouliquen P, Elena PP, Malecaze F. Assessment of the safety and local pharmacokinetics of a 0.15% gel of ganciclovir (Virgan) in healthy volunteers. Invest Ophthalmol Vis Sci 1996;37:S313.
   Web of Science ®Google Scholar
• Naito T, Nitta K, Kinouchi Y, Shiota H, Mimura Y. Effects of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) eye drops and cyclosporine eye drops in the treatment of herpetic stromal keratitis in rabbits. Curr Eye Res 1991;10 Suppl:201–203.
   Google Scholar
• Gordon YJ, Capone A, Sheppard J, Gordon A, Romanowski E, Araullo-Cruz T. 2′-nor-cGMP, a new cyclic derivative of 2′NDG, inhibits HSV-1 replication in vitro and in the mouse keratitis model. Curr Eye Res 1987;6:247–253.
   PubMed Web of Science ®Google Scholar
• Colin J, Hoh HB, Easty DL et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea 1997;16:393–399.
   PubMed Web of Science ®Google Scholar
• Ramirez JB, Baca O, Velasco R, Viggiano D, Erazo J. Topical treatment for epithelial herpetic keratitis: ganciclovir gel vs aciclovir ointment. Invest Ophthalmol Vis Sci 2002;43:E-abstract 3072.
   Google Scholar
• Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2010;12:CD002898.
   Google Scholar
• Foster CS. Ganciclovir gel—a new topical treatment for herpetic keratitis. US Ophthamol Rev Touch Briefings 2008;3:52–56.
   Google Scholar
• Bausch & Lomb, Inc. Ganciclovir reports of postmarketing experience. June 14, 2010.
   Google Scholar
• Laboratoires THEA. Virgan 1.5 mg/g eye gel: pharmacovigilance data. 63017 Clermont-Ferrand Cedex 2, France. February 8, 2008.
   Google Scholar
• Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004;39 Suppl 5:S248–S257.
   Google Scholar
• Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16:114–128.
   PubMed Web of Science ®Google Scholar
• Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008;198:659–663.
   PubMed Web of Science ®Google Scholar
• Tabbara KF. Treatment of herpetic keratitis. Ophthalmology 2005;112:1640.
   PubMedGoogle Scholar
• Tabbara KF, Jarade EF. Ganciclovir effects in adenoviral keratoconjunctivitis. Invest Ophthalmol Vis Sci 2001;42:S579. Abstract 3111-B253.
   Web of Science ®Google Scholar
• Vérin PH, Mortemousque B, Barach D. Ganciclovir 0.15% gel, a new treatment in epidemic keratoconjunctivitis (EKC). Ophthalmic Res 1997;29(suppl 1):12–27.
   Google Scholar
• Sirion Therapeutics, Inc. New drug application for ganciclovir is accepted for review by the FDA for the treatment of ocular herpes [news release]. Medical News Today. January 27, 2009. http://www.medicalnewstoday.com/releases/136720.php. Accessed 15 May 2012.
   Google Scholar
• Bausch + Lomb acquires Zirgan® (ganciclovir ophthalmic gel 0.15%) from Sirion Therapeutics for the treatment of herpetic keratitis [news release]. Rochester, NY: Bausch + Lomb Incorporated; http://bauschlocal.com/zirgan/zirganPressRelease.html. Accessed 15 May 2012.
   Google Scholar
• US Department of Health and Human Services. NDA Approval Letter, Application Number 22–211. Silver Spring, MD: Center for Drug Evaluation and Research. 2009.
   Google Scholar